Osage University Partners — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Addition Therapeuticsadditiontx.comDec 2025
Addition Therapeutics develops genetic medicines using its all-RNA, non-viral, LNP-based PRINT platform, which combines the profile of RNA therapeutics with the durability of gene therapies.
BiotechHealthtechSouth San Francisco, US
Co-investorsSR One Capital ManagementAbingworthPivotal Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.